A nonprofit naloxone producer is celebrating its latest market approval by gifting away 200,000 doses of its over-the-counter nasal spray.
Hurt Discount Therapeutics stated in an announcement that it’s going to donate practically a quarter-million doses of its new product to the Treatment Alliance, a company dedicated to reasonably priced naloxone entry. The announcement comes on the heels of the Meals and Drug Administration’s approval of Hurt Discount Therapeutics’ product RiVive, a brand new nasal naloxone spray used to reverse opioid overdose.
The 200,000-dose donation represents roughly 10% of Hurt Discount Therapeutics’ anticipated annual manufacturing, the nonprofit stated.
“We based Hurt Discount Therapeutics with the singular mission to forestall opioid overdose deaths,” Michael Hufford, the group’s CEO, stated in an announcement. “We’re devoted to creating free or low-cost over-the-counter naloxone nasal spray out there to the communities who want it most.”
RiVive is the second naloxone product to obtain clearance to be bought over-the-counter. The primary, Narcan, obtained FDA approval in March.
Naloxone is considered as a essential part of the U.S. response to the opioid epidemic. However its excessive value has hindered public well being businesses and group teams’ efforts to purchase and distribute the treatment en masse.
The Biden administration has just lately made naloxone pricing a spotlight, convening a gathering of for-profit producers to debate guaranteeing the treatment is financially accessible. That assembly, nevertheless, notably excluded each Treatment Alliance and Hurt Discount Therapeutics.
The assembly got here amid continued criticism that centered specifically on Narcan’s producer. The corporate, Emergent BioSolutions, has lengthy confronted criticism for the value of its nasal spray, which at present retails for anyplace between $38 and $124 per two-pack, in line with the drug pricing web site GoodRx.com. Hufford has stated that Narcan’s excessive value partly impressed his founding the nonprofit, and its improvement of a largely an identical product.
Different producers have additionally rushed to carry naloxone merchandise to the market, together with mechanically advanced, high-dose variations that may price a whole lot and even hundreds of {dollars}. A dose of generic, injectable naloxone, against this, can price only a few {dollars}.
RiVive will probably be bought for as a lot as 40% lower than Narcan, in line with a spokesperson, which means {that a} typical two-pack of the nonprofit’s nasal spray might go for as little as $30 in comparison with a typical Narcan value of $50.
The brand new nasal spray additionally is available in a 3-milligram dose — barely lower than Narcan’s 4 milligrams, and considerably smaller than the upper doses in costly, brand-name merchandise like Kloxxado or Zimhi, which include 8 milligrams and 5 milligrams of naloxone, respectively.
RiVive’s smaller dose permits extra flexibility for folks making an attempt to reverse an overdose, the corporate stated. Whereas it may be administered as many occasions as needed, research present massive naloxone doses usually are not essentially simpler at reversing overdoses. Smaller doses, in the meantime, may help keep away from the extreme withdrawal signs that many individuals expertise upon being revived from an overdose.
Rahul Gupta, the director of the White Home Workplace of Nationwide Drug Management Coverage, applauded RiVive’s approval final month, and inspired extra corporations to work to make naloxone reasonably priced.
“I applaud all corporations working to heed the President’s name to extend entry and affordability of those life-saving medicines, and we urge extra corporations to comply with their lead,” he stated in an announcement. “As we’re seeing overdose dying charges stage off after years of speedy will increase, we should do all the things we will to double down on our efforts to finish this epidemic. As we speak’s approval implies that extra life-saving overdose reversal merchandise will probably be out there over-the-counter for shoppers, and extra competitors available in the market ought to drive down prices.”
STAT’s protection of persistent well being points is supported by a grant from Bloomberg Philanthropies. Our monetary supporters usually are not concerned in any choices about our journalism.
